Work

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Year: 2020

Type: article

Study design: Clinical Trial

Abstract: Aurora A kinase is critical in assembly and function of the mitotic spindle. It is overexpressed in various tumor types and implicated in oncogenesis and tumor progression. This trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of MLN8054, a selective small-molecule inhibitor of Aurora A kinase.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/0e9p-9y82

Authors: Cohen, Roger B., Jones, Suzanne, Eton, Omar, Liu, Hua, Danaee, Hadi, O'Neil, Bert H., Manfredi, Mark, Galvin, Katherine, Burris, Howard, Ecsedy, Jeffrey, Dees, E. Claire, Infante, Jeffrey R., Stringer, Bradley, Von Mehren, Margaret, Fingert, Howard, Lee, Yih

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, Takeda Oncology, National Cancer Institute

Award: G9000018574

OpenAlex ID: W4299911467

FWCI:

Cites:

Cited by: 1

Related to: 10